GlassScriptPhysician profile
Lakimerly M Coates
NPI 1871576264
$3,672.91
in general payments reported to CMS, 2019-2025
29 companies · $23.57 in 2025
The $23.57 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $525 · 2021: $473 · 2022: $459 · 2023: $683 · 2024: $702 · 2025: $23.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.73 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $371.25 | 2019-2025 | Ilumya |
| Amgen INC. | $331.57 | 2019-2023 | Otezla |
| Genzyme Corporation | $285.20 | 2019-2021 | |
| Pfizer INC. | $272.50 | 2020-2024 | |
| Abbvie INC. | $265.24 | 2019-2024 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $255.09 | 2021-2024 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $233.75 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $216.21 | 2022-2024 | Sotyktu |
| Celgene Corporation | $183.49 | 2019 | |
| Janssen Biotech, INC. | $173.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $163.23 | 2020-2024 | |
| Musculoskeletal Transplant Foundation INC. | $133.02 | 2019-2023 | |
| Dermavant Sciences, INC. | $94.51 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.16 | 2023-2024 | Spevigo, Cyltezo |
| Leo Pharma INC. | $79.06 | 2019-2023 | Adbry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.79 | 2020 | |
| Galderma Laboratories, L.P. | $61.90 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $61.18 | 2020-2022 | |
| Incyte Corporation | $50.43 | 2022-2023 | Opzelura |
| Biofrontera INC. | $35.02 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Vyne Pharmaceuticals INC. | $33.62 | 2020-2021 | |
| Journey Medical Corporation | $30.56 | 2022 | |
| Mylan Pharmaceuticals INC. | $23.69 | 2019 | |
| Genentech USA, INC. | $20.04 | 2019 | |
| Almirall LLC | $19.58 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $19.37 | 2019 | |
| Ucb, INC. | $18.92 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $11.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lakimerly Coates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.